Summary & Overview
HCPCS Level II Q5143: Injection, adalimumab-adbm, biosimilar, 1 mg
HCPCS Level II code Q5143 designates the injection of adalimumab-adbm, a biosimilar to adalimumab, measured per 1 mg. As a unit-based HCPCS Level II code for a biologic injectable, it matters nationally because biosimilar adoption and unit-level billing affect drug cost reporting, reimbursement workflows, and inventory management across payers. This code enables payers and providers to track use of a specific adalimumab biosimilar distinct from reference products.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of coding context, payer coverage considerations, and operational implications for administering and billing unit-based biologic injections. The publication summarizes benchmarks and policy-relevant topics such as coding specificity, unit-based charge capture, and the role of biosimilars in cost management. It also outlines clinical context for injectable biologic therapy and typical sites of service where Q5143 is billed.
Where input data is incomplete, the report notes that specific payer policy details, associated taxonomies, ICD-10 pairings, and related service-line entries are not available in the input and should be sourced from payer manuals and clinical documentation for precise coverage and billing rules.
Billing Code Overview
HCPCS Level II code Q5143 describes the injection of adalimumab-adbm, a biosimilar to adalimumab, billed per 1 mg. This code represents a biologic injectable therapy formulation used in conditions for which adalimumab or its biosimilars are indicated.
Service Type: Injectable biologic therapy
Typical Site of Service: Infusion clinic, outpatient clinic, physician office, or other ambulatory care settings where parenteral biologic injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with established moderate-to-severe plaque psoriasis has been prescribed a biosimilar adalimumab product dosed per the specialty pharmacy and clinician. The service described by Q5143 (injection, adalimumab-adbm, biosimilar, 1 mg) represents the billed HCPCS Level II unit for the administered biologic. Typical workflow: the patient arrives at an infusion suite or outpatient clinic for a scheduled subcutaneous biologic injection. A registered nurse verifies identity, reviews allergies and current medications, obtains informed consent for medication administration, and documents baseline vitals. The nurse prepares the prefilled syringe or vial per manufacturer instructions, administers the subcutaneous injection, observes the patient for immediate adverse reactions for 15–30 minutes, and documents lot number, expiration date, dose units billed as Q5143 per milligram, and any patient education provided. Typical sites of service include outpatient clinic, physician office, specialty infusion center, or an accredited community injection suite. Common clinical indications for billing this HCPCS unit include autoimmune inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis where adalimumab therapy is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |